Doma Biopharmaceutical (Suzhou) Co., Ltd, a Chinese pharmaceutical firm, has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial for its innovative bispecific antibody-drug conjugate (ADC), DM005. This development marks a significant milestone for the company as it advances its pipeline towards global clinical stages.
The drug candidate, DM005, is designed to target both the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), exhibiting robust anti-tumor efficacy coupled with an encouraging safety profile in preclinical studies. The upcoming Phase I study is poised to evaluate the therapeutic potential of DM005 in a range of malignancies, including non-small cell lung cancer, head and neck cancer, and digestive tract tumors, among others.- Flcube.com
